EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study

Tae Seo Sohn, Kyung-Ah Han, Yonghyun Kim, Byung-Wan Lee iD, Suk Chon iD, In-Kyung Jeong iD, Eun-Gyoung Hong iD, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh und 1 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15537 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Tae Seo Sohn und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St Mary's Hospital, College of Medicine, The Catholic University…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daewoong Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the long‐term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin in patients with type 2 diabetes mellitus. Materials and Methods After 24 weeks of a randomized, double‐blind treatment period with enavogliflozin 0.3 mg/day (n = 101) or dapagliflozin 10 mg/day (n = 99) added to metformin, all patients received enavogliflozin 0.3 mg/day plus metformin for an additional 28 weeks during the open‐label extension period.

Results

Eighty‐two patients continued enavogliflozin (maintenance group), and 77 were switched from dapagliflozin to enavogliflozin (switch group). All adverse drug reactions (ADR) were mild in severity. In the maintenance group, ADRs (cystitis and vaginal infection) were reported in two patients (2.44%) during 52 weeks. In the switch group, ADR (hypoglycaemia) was reported in one patient (1.30%) during a 28‐week open‐label extension period. At week 52, glycated haemoglobin and fasting plasma glucose were significantly lower than at the baseline, by 0.85% and 29.08 mg/dl, respectively, in the maintenance group ( p < .0001 for both), and by 0.81% and 32.77 mg/dl, respectively, in the switch group ( p < .0001 for both). At week 52, 68.92% of patients from the maintenance group and 64.29% from the switch group achieved glycated haemoglobin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2GlucosidesHypoglycemic AgentsMetforminAdultAgedFemaleHumansMaleMiddle AgedBenzofuransBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationGlycated HemoglobinHypoglycemiaSodium-Glucose Transporter 2 InhibitorsTreatment Outcome

Stichwörter der Autor:innen

dapagliflozinenavogliflozinhypoglycaemic agentsmetforminrandomized controlled trialsodium‐glucose transporter 2 inhibitorstype 2 diabetes mellitus

Substanzen

Benzhydryl CompoundsBenzofuransBlood GlucosedapagliflozinEnavogliflozinGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsMetformin

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu St Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, South Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University, Seoul, South Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Bundang Jesaeng Hospital, Seongnam, South Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.

ORCID-Profile: Byung-Wan Lee, Suk Chon, In-Kyung Jeong, Eun-Gyoung Hong, Kun-Ho Yoon

Förderung

  • Daewoong Pharmaceutical Company

Zitieren

APA

Sohn, T. S., Han, K. A., Kim, Y., Lee, B. W., Chon, S., Jeong, I. K., Hong, E. G., Son, J. W., Na, J., Cho, J. M., In Cho, S., Huh, W., & Yoon, K. H. (2024). A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15537

Vancouver

Sohn TS, Han KA, Kim Y, Lee BW, Chon S, Jeong IK, et al. A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15537

BibTeX
@article{Sohn2024,
  author = {Sohn, Tae Seo and Han, Kyung-Ah and Kim, Yonghyun and Lee, Byung-Wan and Chon, Suk and Jeong, In-Kyung and Hong, Eun-Gyoung and Son, Jang Won and Na, JaeJin and Cho, Jae Min and In Cho, Seong and Huh, Wan and Yoon, Kun-Ho},
  title = {A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15537}
}
Kostenlos starten →